Baseline Serum Albumin Is a Predictive Biomarker for Patients With Advanced Pancreatic Cancer Treated With Bevacizumab: A Pooled Analysis of 7 Prospective Trials of Gemcitabine-Based Therapy With or Without Bevacizumab

BACKGROUND: Phase 3 studies of bevacizumab in patients with advanced pancreatic cancer (APCA) demonstrated no improvement in outcome. To the authors’ knowledge, no validated predictive biomarkers for bevacizumab exist, although emerging data suggest that subsets of patients with APCA may benefit fro...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancer
Päätekijät: Pant, Shubham, Martin, Ludmila K., Geyer, Susan, Wei, Lai, Van Loon, Katherine, Sommovilla, Nilli, Zalupski, Mark, Iyer, Renuka, Fogelman, David, Ko, Andrew H., Bekaii-Saab, Tanios
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2014
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4265390/
https://ncbi.nlm.nih.gov/pubmed/24633933
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.28648
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia